New drug duo aims to stop stomach cancer from coming back
NCT ID NCT07474324
First seen Mar 21, 2026 · Last updated May 17, 2026 · Updated 5 times
Summary
This study tests whether adding the targeted drug disitamab vedotin to standard chemotherapy (SOX) after surgery can help prevent stomach cancer from returning. It is for people with stage III HER2-positive stomach cancer who have had their tumor fully removed. The trial will compare the combination against chemotherapy alone in about 124 participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GC/GEJC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
The First Affiliated Hospital with Nanjing Medical University
RECRUITINGNanjing, Jiangsu, 210000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.